JP2002539781A5 - - Google Patents

Download PDF

Info

Publication number
JP2002539781A5
JP2002539781A5 JP2000606725A JP2000606725A JP2002539781A5 JP 2002539781 A5 JP2002539781 A5 JP 2002539781A5 JP 2000606725 A JP2000606725 A JP 2000606725A JP 2000606725 A JP2000606725 A JP 2000606725A JP 2002539781 A5 JP2002539781 A5 JP 2002539781A5
Authority
JP
Japan
Prior art keywords
sequence
gln
lys
gly
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000606725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002539781A (ja
JP4237945B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/006574 external-priority patent/WO2000056866A2/en
Publication of JP2002539781A publication Critical patent/JP2002539781A/ja
Publication of JP2002539781A5 publication Critical patent/JP2002539781A5/ja
Application granted granted Critical
Publication of JP4237945B2 publication Critical patent/JP4237945B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000606725A 1999-03-19 2000-03-14 Akt核酸、ポリペプチドおよびその使用 Expired - Fee Related JP4237945B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19
US60/125,108 1999-03-19
PCT/US2000/006574 WO2000056866A2 (en) 1999-03-19 2000-03-14 Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (3)

Publication Number Publication Date
JP2002539781A JP2002539781A (ja) 2002-11-26
JP2002539781A5 true JP2002539781A5 (enExample) 2005-04-21
JP4237945B2 JP4237945B2 (ja) 2009-03-11

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000606725A Expired - Fee Related JP4237945B2 (ja) 1999-03-19 2000-03-14 Akt核酸、ポリペプチドおよびその使用

Country Status (18)

Country Link
EP (1) EP1144600B1 (enExample)
JP (1) JP4237945B2 (enExample)
KR (1) KR100700908B1 (enExample)
AT (1) ATE402995T1 (enExample)
AU (1) AU782448B2 (enExample)
BR (1) BR0009170A (enExample)
CA (1) CA2343074C (enExample)
CY (1) CY1108459T1 (enExample)
DE (1) DE60039677D1 (enExample)
DK (1) DK1144600T3 (enExample)
ES (1) ES2310515T3 (enExample)
HK (1) HK1041288B (enExample)
IL (4) IL141984A0 (enExample)
NO (1) NO20014537L (enExample)
PT (1) PT1144600E (enExample)
SI (1) SI1144600T1 (enExample)
WO (1) WO2000056866A2 (enExample)
ZA (1) ZA200108414B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
WO2000062605A1 (en) 1999-04-16 2000-10-26 Yale University eNOS MUTATIONS USEFUL FOR GENE THERAPY AND THERAPEUTIC SCREENING
WO2000077190A2 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
JPWO2003063905A1 (ja) * 2002-01-31 2005-05-26 株式会社東京大学Tlo 免疫疾患の予防又は治療剤
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
EP1661581A1 (en) * 2003-07-28 2006-05-31 Osaka Industrial Promotion Organization Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same
EP2599793A1 (en) * 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-phospho-akt antibodies
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
CN102985418B (zh) 2010-07-02 2015-09-09 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
ES2731602T3 (es) 2014-09-24 2019-11-18 Gilead Sciences Inc Métodos para tratar la enfermedad hepática
CA3100432C (en) 2014-12-23 2023-08-08 Gilead Sciences, Inc. Processes for preparing ask1 inhibitors
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
WO2020180886A1 (en) * 2019-03-04 2020-09-10 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the akt pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
DE69633186T2 (de) * 1995-11-16 2005-08-18 Novartis Ag Methode zur Identifizierung von Verbindungen die mit RAC Proteine Kinase interagieren
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
WO2000077190A2 (en) * 1999-06-11 2000-12-21 Aventis Pharmaceuticals Products Inc. Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Similar Documents

Publication Publication Date Title
JP2002539781A5 (enExample)
JP5451960B2 (ja) 酵母におけるhpv45l1の最適化された発現
CN115246874B (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
KR0164215B1 (ko) 사람 유두종바이러스 제16형 e7 단백질상의 면역원성 서열을 갖는 폴리펩타이드
WO2022206222A1 (zh) 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用
JP2008536483A5 (enExample)
JP2006501825A5 (enExample)
JP2024180560A5 (enExample)
CA2343074A1 (en) Akt nucleic acids, polypeptides, and uses thereof
CN114891119A (zh) 降解PD-L1的生物大分子靶向蛋白水解嵌合体BioPROTAC及其制备方法和应用
CN101062952B (zh) 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用
CN114560915A (zh) 一种改造的高滴度SARS-CoV-2假病毒
CN106164090B (zh) TRAIL穿膜肽样突变体MuR6、制备方法及应用
US10548973B2 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
Günther et al. Protein and peptide delivery via engineered polyomavirus‐like particles
Rueda et al. Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles
CA2098926A1 (en) Medicaments for the treatment of papillomavirus diseases
US20090155853A1 (en) Non-viral gene delivery complex
JP2003507029A5 (enExample)
JPS6312299A (ja) ポリペプチドの生産のための発現ベクタ−、ポリペプチドの交換発現法、発現ベクタ−を含有する宿主、それによりつくられた生産物
CN102643349B (zh) 携带乙肝病毒抗原表位的重组嵌合蛋白及其制备
CN106459172A (zh) 一种TRAIL双靶点突变蛋白MuR5S4TR、其制备方法及其应用
JP2004518410A5 (enExample)
KR100785397B1 (ko) 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
CN119798408B (zh) 一种识别hpv多抗原表位的tcr及其编码序列